Oncolytics Biotech Q3 EPS Loss Widens To $(0.10)
Portfolio Pulse from Benzinga Newsdesk
Oncolytics Biotech reported a wider loss in Q3 with an EPS of $(0.10).
November 03, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Oncolytics Biotech's Q3 earnings per share (EPS) loss has widened to $(0.10).
A widening loss in Q3 indicates that Oncolytics Biotech's financial performance has deteriorated, which could negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100